Hemophilia A occurs due to a factor VIII deficiency. It is an X-linked chromosomal disease also known as classic hemophilia. Patients inherit the condition as an X-linked trait, and as a result, males are primarily affected by the condition, while females are the carriers of the trait. The condition generally involves genetic inheritance, wherein the trait is passed onto the children by parents. About 33% of the cases involve spontaneous mutation. Individuals who are affected suffer hemorrhage into joints and muscles, easy bruising, and prolonged bleeding from wounds.
Low diagnosis rate is a key contributor driving the hemophilia A treatment market globally. According to a World Federation of Hemophilia 2017 report, globally, there are around 400,000 patients with hemophilia. Out of the total population of hemophilia patients, hemophilia A patients account for around 80%. Hemophilia A is about four times as common as hemophilia B and occurs in 1 in 5,000 live male births. Globally, only about 30% of patients with hemophilia are diagnosed, partly due to lower awareness levels about the condition among the general population. Hemophilia patients exhibit three forms of the condition: mild, moderate, or severe, depending on the level of clotting factor in the blood. A severe form of the condition affects 40% of hemophilia patients, who are vulnerable to several bleeds per month without treatment. Mild and moderate hemophilia can go undiagnosed for years due to variable bleed rates, thus affecting the overall diagnosis rate. Geographically, developed countries have a relatively higher diagnosis rate as compared to developing countries, owing to increased government initiatives for improving hemophilia awareness levels among the general population. With an increase in initiatives aimed at improving awareness levels about hemophilia, the diagnosis rate is expected to rise, in turn, boosting demand for therapies used for managing this condition.
Hemophilia drug manufacturers and government and non-government organizations are focusing on nationwide campaigns to create awareness about the condition among the general population. Each year, April 17th is observed as World Hemophilia Day. On this day, organizations such as the World Federation of Hemophilia (WFH) and local governments and other groups in different countries come together to raise public awareness among the hemophilia community. National news media campaigns and social media campaigns have been used to educate people with hemophilia to help them effectively monitor and manage this condition.
The global hemophilia A treatment market can be segmented based on product, distribution channel, and geography. In terms of product, the global hemophilia A treatment market can be divided into recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, and others. Based on distribution channel, the global hemophilia A treatment market can be divided into retail pharmacies, hospital pharmacies, and others.
In terms of geography, the global hemophilia A treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global hemophilia A treatment market due to the presence of a large patient pool suffering from hemophilia A in the region and ongoing research to develop new treatment options for managing the condition. For example, in August 2018, the U.S. Food and Drug Administration (FDA) had approved Jivi (formerly BAY94-9027) used for the treatment and prophylaxis of bleeding in previously treated patients above the age of 12 years with hemophilia A. Jivi helps in replacing missing or reduced Factor VIII (FVIII), an important blood clotting protein in patients with the bleeding condition. North America was followed by Europe and Asia Pacific. In Asia Pacific, a considerable population of patients with hemophilia A and a rise in diagnosis rate are likely to fuel the hemophilia A treatment market during the forecast period.
Prominent players operating in the global hemophilia A treatment market include Pfizer, Inc., Kedrion, CSL Behring, Shire Plc., Bayer AG, Novo Nordisk A/S, Sanofi, and F. Hoffmann-La Roche Ltd..
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.